Home » Market News » DirectorsTalk Highlights » EpiSwitch Technology
Oxford BioDynamics

EpiSwitch Technology

EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). 

CCSs can provide a compelling, stable framework from which changes in the regulation of a genome can be analysed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.